3.160USDMkt Cap: 131.59M USDP/E: 1.53Last update: 2026-05-21
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap131.59M USD
Enterprise Value130.91M USD
Revenue (TTM)123.87M USD
Gross Profit33.84M USD
Net Income (TTM)115.00K USD
Revenue/Share3.742 USD
Last Price3.160 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00847G7051
Valuation
P/E (Trailing)1.53
P/E (Forward)-1.37
PEG1.44
EV/EBITDA8.62
EV/Revenue1.06
P/S1.06
P/B-0.55
EPS (TTM)2.05
EPS (Forward)-2.30
52W Range
3.08064% of range3.205
52W High3.205 USD
52W Low3.080 USD
Profitability
Gross Margin29.63%
Oper. Margin44.62%
EBITDA Margin12.26%
Profit Margin0.10%
ROE-0.04%
ROA0.05%
Growth
Revenue Growth40.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.19M USD
CapEx (TTM)6.00K USD
FCF Margin-40.88%
FCF Yield-38.48%
Net Debt6.08M USD
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity-0.21
Current Ratio0.38
Quick Ratio0.36
Book Value/Sh-5.7430 USD
Cash/Share0.8400 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateApr 12, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)15.50 USD
Target Range8.000 USD – 23.00 USD
# Analysts2
Ownership
Shares Out.41.64M
Float38.63M
Insiders6.68%
Institutions23.23%
Short Interest
Short Ratio4.0d
Short % Float10.70%
Short % Out.10.56%
Shares Short4.39M
Short (prev mo.)4.28M
Technical
SMA 503.764 (-16.0%)
SMA 2003.851 (-17.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)429.40K
Avg Vol (10d)758.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—